Project Grant R61HL180327
Award Date 9/4/25
Completion Date 8/31/27
Dollars Obligated $445K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded Revidia Therapeutics, Inc. a $1,358,179 Project Grant to conduct IND-enabling safety and toxicity testing of a subcutaneous formulation of the PTP1B inhibitor MSI-1436. This novel therapy aims to treat fatal cardiomyopathy in patients with Duchenne muscular dystrophy (DMD), a leading cause of mortality in this population. The proposed studies will...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $715,161 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis), to conduct research on the epigenetic regulation of pulmonary smooth muscle cell remodeling in pulmonary hypertension. The research aims to elucidate the molecular mechanisms by which the sphingosine kinase 2 (SPHK2) enzyme contributes to vascular...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $637,126 to the Trustees of Indiana University, doing business as Indiana University Indianapolis, to conduct research on the regulatory mechanisms of neovascularization, cardiomyocyte survival, and endothelial cell-cardiomyocyte crosstalk in myocardial infarction. The project aims to elucidate the roles of novel endothelial cell- and cardiomyocyte-specific...
- This $131,085 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports a 5-year research project led by Dr. Arianne Caudal at The Leland Stanford Junior University to elucidate the cardiac-protective mechanisms of SGLT2 inhibitors. The project aims to leverage human induced pluripotent stem cell-derived cardiovascular cells, single-cell RNA sequencing, metabolomics, and large-scale drug-protein interaction determination to...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $596,401 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Trustees of Indiana University, doing business as Indiana University Indianapolis, to conduct research on a novel long non-coding RNA called MCRL1 and its role in regulating human cardiac and hematopoietic differentiation. The research project aims to investigate how MCRL1 interacts with the Wnt/β-catenin pathway and the epigenetic...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $651,349 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to the Regents of the University of Michigan. The funding supports a research project titled "Stoichiometric, Adhesion, and Contractile Deficits in Desmoplakin Cardiomyopathy" from August 1, 2025 through May 31, 2029. The project aims to investigate the mechanistic links between genetic variants in the desmoplakin (DSP) gene and the...
- The National Heart Lung and Blood Institute (NHLBI) awarded a $711,039 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Research Institute at Nationwide Children's Hospital. The award supports research to determine the functions of the cardiac m6A methyltransferases METTL3 and METTL14 in early myocardial development, and whether their dysregulation contributes to the pathogenesis of fetal dilated cardiomyopathy (DCM). The proposed study leverages mouse...
- This federal Project Grant award of $414,996.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research on the mechanisms of junctional proteins in post-surgical lymphedema. The award is held by the Trustees of Indiana University, doing business as Indiana University Indianapolis, and runs from August 15, 2025 through May 31, 2030. The research aims to investigate the role of lymphatic capillary junctional proteins in the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $749,360 to the University of Cincinnati to investigate the role of the glucose transporter GLUT1 in the development of diabetic cardiomyopathy. The research aims to delineate the signaling and metabolic pathways through which GLUT1-mediated glucose uptake leads to cardiac toxicity in diabetes, as well as explore the therapeutic potential of GLUT1 inhibition. Key...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), awarded a $107,834 project grant to The Leland Stanford Junior University. The grant, which runs from January 21, 2025 to January 2, 2026, aims to investigate the cardiovascular impact of novel gut-hormone agonists, including semaglutide (GLP-1R), tirzepatide (GLP-1R/GIPR), and retatrutide (GLP-1R/GIPR/GCGR). The research will involve comprehensive profiling of...